← Leaderboards
Chin-Ho Chen
Meharry Medical College
$11,542,647
Attributed
$11,763,772
Total exposure
12
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $685K · FY2005–23$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$11,763,772 · 12
By mechanism
R01$9,925,761 · 7
R21$875,876 · 2
R56$444,344 · 1
S06$296,826 · 1
R29$220,965 · 1
Top collaborators
- Li Huang2 shared
Others in their field
Top investigators on “Drug Resistance”
- Judith S. Currier · University Of California Los Angeles$207,752,958
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$145,910,108
- Ralph Parchment · Leidos Biomedical Research, Inc.$140,676,376
- Daniel R Kuritzkes · Brigham And Women'S Hospital$114,882,802
- Peter C Adamson · National Childhood Cancer Foundation$114,476,581
- Wafaa M. El-Sadr · Columbia University Health Sciences$113,453,088
Research focus
Drug ResistanceVirus ReplicationPharmaceutical PreparationsDrug CandidateHuman Immunodeficiency Virus 1Drug DevelopmentEffectivenessAntiviral AgentsHiv-1ExhibitsBaseDrug Resistant VirusScaffoldViralModificationLeadStructure-Activity RelationshipResistanceVirusAids TherapyInhibitor/AntagonistBetulinic AcidSuccessAmino Acids
Grant awards (46)
New Non-Nuceleotide Reverse Transcriptase Inhibitors for Drug Resistant HIV Strains$521,364
R01 · FY2023 · AI · contact PI
New Non-Nuceleotide Reverse Transcriptase Inhibitors for Drug Resistant HIV Strains$509,196
R01 · FY2022 · AI · contact PI
New Non-Nuceleotide Reverse Transcriptase Inhibitors for Drug Resistant HIV Strains$524,446
R01 · FY2021 · AI · contact PI
Small Molecule HIV-1 Entry Inhibitor with Novel Mechanisms of Action$418,313
R01 · FY2020 · AI · contact PI
Aloperine derivatives as novel anti-influenza agents$201,250
R21 · FY2020 · AI
Small Molecule HIV-1 Entry Inhibitor with Novel Mechanisms of Action$418,639
R01 · FY2019 · AI · contact PI
Aloperine derivatives as novel anti-influenza agents$241,000
R21 · FY2019 · AI
Small Molecule HIV-1 Entry Inhibitor with Novel Mechanisms of Action$440,001
R01 · FY2018 · AI · contact PI
Quinolizidines as Novel HIV-1 Entry Inhibitors$444,344
R56 · FY2016 · AI · contact PI
Intervening with Latent HIV-1 Infection using Gnidimacrin$198,126
R21 · FY2015 · AI · contact PI
Betulinic acid derivatives as anti-HIV agents$386,100
R01 · FY2014 · AI · contact PI
Intervening with Latent HIV-1 Infection using Gnidimacrin$235,500
R21 · FY2014 · AI · contact PI
Betulinic acid derivatives as anti-HIV agents$362,934
R01 · FY2013 · AI · contact PI
Betulinic acid derivatives as anti-HIV agents$386,100
R01 · FY2012 · AI · contact PI
Small Molecules that Regulate Proteasome Activity$298,871
R01 · FY2012 · GM · contact PI
Betulinic acid derivatives as anti-HIV agents$386,100
R01 · FY2011 · AI · contact PI
Small Molecules that Regulate Proteasome Activity$298,871
R01 · FY2011 · GM · contact PI
Betulinic acid derivatives as anti-HIV agents$367,600
R01 · FY2010 · AI · contact PI
Small Molecules that Regulate Proteasome Activity$301,890
R01 · FY2010 · GM · contact PI
Small Molecules that Regulate Proteasome Activity$316,000
R01 · FY2009 · GM · contact PI
Betulinic acid derivatives as anti-HIV agents.$297,196
R01 · FY2009 · AI · contact PI
Small Molecules that Regulate Proteasome Activity$49,900
R01 · FY2009 · GM · contact PI
Betulinic acid derivatives as anti-HIV agents.$297,196
R01 · FY2008 · AI · contact PI
Betulinic acid derivatives as anti-HIV agents.$302,547
R01 · FY2007 · AI · contact PI
Betulinic acid derivatives as anti-HIV agents.$310,583
R01 · FY2006 · AI · contact PI
Dynamic envelope interactions and HIV-1 neutralization.$263,168
R01 · FY2006 · AI · contact PI
TM-SU Interaction in the Native HIV/SIV Env$308,000
R01 · FY2005 · AI
Dynamic envelope interactions and HIV-1 neutralization.$269,500
R01 · FY2005 · AI
TM-SU Interaction in the Native HIV/SIV Env$308,000
R01 · FY2004 · AI
Dynamic envelope interactions and HIV-1 neutralization.$269,500
R01 · FY2004 · AI
TM-SU Interaction in the Native HIV/SIV Env$308,000
R01 · FY2003 · AI
Dynamic envelope interactions and HIV-1 neutralization.$235,387
R01 · FY2003 · AI
The molecular target of the HIV entry inhibitor IC9564$152,921
R01 · FY2003 · AI
The molecular target of the HIV entry inhibitor IC9564$82,078
R01 · FY2003 · AI
Dynamic envelope interactions and HIV-1 neutralization.$17,487
R01 · FY2003 · AI
The molecular target of the HIV entry inhibitor IC9564$235,516
R01 · FY2002 · AI
POTENT NOVEL ANTI HIV 1 AGENTS--MECHANISM OF ACTION$0
S06 · FY2002 · GM
POTENT NOVEL ANTI HIV 1 AGENTS--MECHANISM OF ACTION$0
S06 · FY2002 · GM
POTENT NOVEL ANTI HIV 1 AGENTS--MECHANISM OF ACTION$0
S06 · FY2002 · GM
The molecular target of the HIV entry inhibitor IC9564$282,357
R01 · FY2001 · AI
POTENT NOVEL ANTI HIV 1 AGENTS--MECHANISM OF ACTION$179,091
S06 · FY2001 · GM
NEUTRALIZATION DETERMINANTS OF A PRIMARY HIV-1 ISOLATE$107,060
R29 · FY2001 · AI
POTENT NOVEL ANTI HIV 1 AGENTS--MECHANISM OF ACTION$0
S06 · FY2001 · GM
POTENT NOVEL ANTI HIV 1 AGENTS--MECHANISM OF ACTION$0
S06 · FY2001 · GM
POTENT NOVEL ANTI HIV 1 AGENTS--MECHANISM OF ACTION$117,735
S06 · FY2000 · GM
NEUTRALIZATION DETERMINANTS OF A PRIMARY HIV-1 ISOLATE$113,905
R29 · FY2000 · AI